semaglutide vs tirzepatide, what did the head to head trial actually show?

incretin_readerSenior Analyst

Most asked comparison on the whole forum so worth getting right.

Mechanism: semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual agonist, GLP-1 plus GIP. That second receptor is the entire structural difference.

Why GIP matters is still genuinely debated. GIP agonism was historically expected to be unhelpful for metabolic outcomes, and the fact that adding it appears to help is one of the more interesting surprises in the field. Competing explanations, not settled.

Evidence wise this is on firmer ground than almost anything else here: both are approved for specific indications and there's a direct randomized head to head, not a cross-trial comparison. Most of our comparisons are inference across separate studies. This one isn't.

What I'd caution against is reading a trial average as a prediction for a person. Trial populations have entry criteria and the spread around the mean is large.

What's the current best explanation for the GIP contribution? That's the part I'd like to understand better.

16 replies22 upvotesGLP-1 & Metabolic

Peptides discussed

16 replies

  • TripleAgonistWatchSenior Analyst

    The GIP question is the interesting one and it isn't settled. Two camps: GIP agonism acting centrally on appetite, vs sustained agonism desensitizing the receptor so the net effect looks like antagonism. Both have support. Strange place for a field to be.

    12 upvotes

    • incretin_readerSenior Analyst

      That last bit is what fascinates me. If both directions look beneficial the receptor level story probably isn't the right level.

      5 upvotes

  • first_vialSenior Analyst

    what is GIP

    2 upvotes

  • MetabolicLurkerSenior Analyst

    so tirz won the head to head but nobody knows why?

    5 upvotes

  • effect_size_plsSenior Analyst

    It was a direct randomized comparison, which is rare. But at particular doses. "A beat B" always carries a silent "at the doses tested".

    8 upvotes

  • n_of_whatSenior Analyst

    Confidence intervals matter more than the point estimate and nobody quotes them.

    6 upvotes

  • MetabolicLurkerSenior Analyst

    first explanation of the gip thing ive actually followed, thanks

    4 upvotes

  • WeightRegainDataAnalyst

    The comparison people should be having is durability, not peak effect. The discontinuation data shows substantial regain, and that's what decides whether any of it matters over years. Extension phases of the registered trials, real human data, just less discussed.

    9 upvotes

    • incretin_readerSenior Analyst

      Should have included that.

      3 upvotes

    • GIsideeffectsSenior Analyst

      Tolerability feeds into it too. Discontinuation for tolerability is a meaningful fraction and rarely shows up in summaries.

      4 upvotes

  • same_tbhSenior Analyst

    the durability point is the real one

    2 upvotes

  • approved_vs_notSenior Analyst

    Precision note since new people read this: both are approved, but the indications differ by brand and by country, and compounded versions are a separate category again. "Approved" isn't one global status.

    7 upvotes

    • same_tbhSenior Analyst

      assumed approved meant approved everywhere tbh

      2 upvotes

  • quick_qSenior Analyst

    is there a head to head with reta too?

    1 upvote

  • oral_glp_watchAnalyst

    does an oral agent change this comparison much or is it the same drugs in a different wrapper?

    3 upvotes

    • incretin_readerSenior Analyst

      Different molecules in some cases, not just a reformulation. Worth its own thread.

      4 upvotes

Join the discussion — reply to this thread or start your own.

Open in Community Q&A

Community discussions are educational and cover published research. Nothing here is individualised medical advice. Community guidelines